GlaxoSmithKline (NYSE:GSK) and Theravance (NASDAQ:THRX) said Wednesday that their combined treatment for patients with chronic obstructive pulmonary disorder and asthma posted strong results in a clinical study.
In the phase II study, the drug, Relovair, showed a comparable effect on heart function and safety to placebo, with the most common side effects being nasopharyngitis and headaches.
A larger amount of patients in the Relovair group, 68%, versus 50% in the placebo group, reported adverse events.
Patients treated with Relovair however, showed greater improvements in lung function compared with placebo.
Darrell Baker, vice president of Respiratory Medicines Development Centre, said the data is “encouraging” and shows potential for Relovair’s use as the first once-daily combination in patients with COPD.
The companies presented the findings of the combined drug at the European Respiratory Society congress in Barcelona.